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Summary
The decay rate of thrombin in plasma is shown to be linearly
proportional to the concentration of antithrombin III (AT III),
not only in the absence but also in the presence ofheparin. This is
a consequence of partitioning of heparin between AT III and
other plasma proteins.
In previous articles we calculated the prothrombin converting
activity assuming a fixed concentration of AT III. Since AT III is
consumed during the clotting process, prothrombinase activity is
more accurately approximated using an algorithm that counts
with the decrease of the AT III concentration. It is shown this
leads to higher prothrombinase activities. The (absence of)
inhibition of prothrombin conversion by prothrombinase in the
presence of heparins found with the previous method is also found
using the new algori thm.
From the results presented it is evident that characteristic
parameters of heparin action have to be normalised to the AT III
concentration. On this basis we define a Standard Independent
Unit of the antithrombin activity of heparin.
Introduction
The understanding of the action of heparins in plasma requires
a detailed analysis of the influence of heparin on thrombin decay.
We have previously described how we determined the pseudo
first-order decay constant (ka.") of endogeneously generated
thrombin in plasma, in the absence and in the presence of
heparins. In the course of the thrombin generation process we
stopped prothrombin conversion via inhibition of factor Xa with
soybean trypsin inhibitor and determined the velocity of decay of
the remaining thrombin (1, 2). We showed that the global decay
constant thus obtained is the sum of the decay constant (k2)
caused by o2-macroglobulin (o2M) and an o2M-independent decay
constant (k1). The latter consists of an AT Ill-independent part
(-rc%) and an AT Ill-dependent part (-90%). The AT III-
independent part is caused by various inhibitors, mainly by o1-
antitrypsin (1), but not by heparin cofactor II (HC II) because, at
heparin concentrations <2Ulml, as used in this article, the
stimulation of HC II is negligible (3) We therefore can describe
the increase of thrombin decay brought about by the addition of
heparin in terms of the acceleration of AT III dependent inactiva-
tion.
The level of AT III antigen in serum is significantly smaller
than the initial plasma level (4, 5) because AT III is consumed
during the coagulation process. ln this article we wanted to
investisate in detail whether the decrease of AT III durins the
coagulation process does affect the decay constant of thrombin in
the presence of heparin.
The answer is not obvious a priori. In previous work we
observed no variation of k6." between 4 and 7 min after the start
of thrombin generation, i. e. after the thrombin peak concentra-
tion has occurred. In the absence of heparin one might expect k1
to decrease proportionally with the AT III concentration during
the coagulation process since k1 is the product of a second order
decay constant k1' and the AT III concentration. In the presence
of heparin the question is more complicated. The 2 pM of AT III
present in plasma represent a large molar excess over 1 U/ml of
heparin (1 U/ml : 110 nM AT III binding standard heparin).
The heparin-catalysed interaction of AT III and thrombin was
shown to be saturable with respect to both AT III and thrombin
and the apparent dissociation constant of the functional AT III-
heparin complex is -160 nM (6-10). This means that the normal
plasma level of AT III could be expected to bind virtually all
heparin up to 1 U/ml and even higher. The rate of thrombin
inactivation then should be proportional to the concentration of
heparin only, and not depend any more on the AI III concentra-
t ion.
In plasma, however, other heparin binding proteins may
compete for heparin. The outcome of this competition is depen-
dent upon the affinity constants and concentrations of all heparin
binding proteins and no reasonable guess can be made on the
influence ofAT III concentration on k4"". Therefore we reinvesti-
gated in detail the course of ft6.. during the coagulation process
and its dependence on AI III and heparin concentration.
Materials and Methods
Chemicals
The chromogenic substrate for thrombin was H D-Phe-Pip-Arg-pNA
(52238) from Kabi, Sweden. The 4th International heparin standard (4th
I. S. H.) was from the National Institute for Biological Standards and
Control. Reptilase was obtained from Laboratoires Stago (Asnidres.
France), a solution was made according to the instructions of the
manufacturer. Soybean trypsin inhibitor (batch No.43 F-800) was
obtained from Sigma (St. Louis, MO).
Blood and Products
Blood from 10 healthy donors was collected on 0.13 M trisodium
citrate; nine parts of blood to one part of citrate solution
Platelet poor plasma (PPP) was obtained after two centrifugations at
900 x g, 15" C for 15 min and a third centrifugation at 23,000 x 9,4' C,
for t h. PPP was pooled and stored at -80'C It was checked that the
clotting factors and the antiproteases were in the normal range.
Defibrinated plasma was obtained by mixing an aliquot of plasma with
1 :50 volume of a reptilase solution, letting a clot form for 5 min at 37" C
and keeping the clotted plasma at 0' C for 10 min. The fibrin clot formed
was discarded by winding it on a small plastic spatula. The concentration
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Fig. 1 The course of the endogenous thrombin decay constant during the
thrombin generation test. The total constant (k1 + kz + k3) is given, as
obtained after inhibiting thrombin generation by addition of SBTI
(16.5 pM final concentration). I Thrombin generation test in normal
plasma. * k6." in normal plasma ! Idem with 0 03 U/ml heparin
adding 0 25 vol of diluted human brain thromboplastin in 100 mM of
CaCl2to 1 vol of euglobulin fraction.
Human brain thromboplastin was prepared according to Owren and
Aas (12).
Determination of Thrombin Generation in Plasma
To 240 1tl of defibrinated plasma are added 60 pl of 50 mM Tiis-HCl,
100 mM NaCl, 0.5 mg/ml ovalbumin, pH 7.35 (buffer A), containing
heparin at the desired concentration. Thrombin formation is started by
the addition of 60 pl of a solution containing 100 mM of CaCl2 and human
brain thromboplastin, diluted so as to clot the uninhibited, non-defibri-
nated reaction mixture in 70 s (final dilution -L:240). At intervals a 10 pl
aliquot of the mixture is sampled into a disposable plastic cuvette
containing 465 pl of 50 mM Tiis-HCl, 100 mM NaCl, 20 mM EDTA,
0.5 mg ovalbumin/ml, pH 7.90 (buffer B) and 25 pl of 52238 (4 mM) and
prewarmed for at least 5 min at 37" C. AfIer about 120 s the reaction in
the cuvette is stopped by adding 300 pl of concentrated acetic acid. The
precise moments of sampling and stopping were recorded on a personal
computer by means of pushbutton equipped pipettes. Optical densities are
read at 405 nm in a dual wavelength (405 nm-536 nm) dedicated instru-
ment constructed in our workshop. From the optical density and the start
and stop times, the amidolytic activities (mOD/min) were calculated. The
amidolytic activity is the result of a) free thrombin and b) o2 macroglobu-
lin bound thrombin (o2M-T). At the end of the coagulation process a
stable endlevel of amidolytic activity is obtained, due to the o2M-T
complex formed. k2 in our batch of normal plasma, determined according
to Hemker et al. (1), equalled 0.23 min-l and was independent of the
heparin concentration.
The Pseudo First Order Rate Constant of Thrombin Inactivation
Endogenous thrombin. Defibrinated plasma (120 pl) was incubated
with 14 pl of buffer A. Thrombin generation was started as described in
the previous section At a timepoint when the concentration of thrombin
was sufficiently high, 6 pl of Soybean Trypsin Inhibitor (SBTI) solution
(10 mg/ml) and 10 pl of buffer containing the required amount of heparin
were added. SBTI at this concentration was shown to block the activity of
prothrombinase completely and instantaneously and not to influence the
activity of thrombin on chromogenic substrate (1) At suitable time
intervals (2-10 s) after addition of the SBTI solution, 10 pl aliquots were
drawn for measurement of thrombin concentrations, as described above.
Exogenous thrombin. A mixture of 120 pl of defibrinated human
plasma and 40 pl of buffer A with or without heparin was prewarmed for
2 min at 37' C, then 20 pl of a thrombin preparation were added to so as
to obtain a final concentration of 100 nM The disappearance of thrombin
was then measured as described above.
In order to approach the experimental conditions of endogenous
thrombin decay as closely as possible, we have not used purified thrombin
but thrombin that was freshly generated either in a euglobulin fraction
(see above) or in plasma (same conditions as in the thrombin generation
experiments).
In both methods the amidolytic activities (C,) as obtained in the
experiment, were fitted to the three parameter curve C, : C- + (Co -
C-) e-k', where k : kd".: k1 + k2 (see introduction). C6 is the initial
amidolytic actiyity C* is the residual, steady end-level activity due to the
o2M-T complex. In our hands, the standard error of a single estirpation is
below 7"/o as long as half life times exceed 4 s (ft6." : 10 min-r). At
shorter half life times it increases proportionally with k6.., with about 1%
'  - 1Der mln - .
Determination of AT III in Plasma and in Serum
The functional assay is essentially the titration of an unknown amount
of AT III with a known. excess amount of thrombin. 100 pl of a suitable
dilution of the sample (1 :100 to 1:800) in buffer B containing 2 U/ml
standard heparin, with 100 pl of a 20 nM thrombin solution were
incubated at37' C in a plastic spectrophotometer cuvette during 10 min.
Then 300 pl of 330 pM 52238 in buffer B were added, and the residual
thrombin induced amidolytic activity was measured at 405 nM in a
spectrophotometer thermostated at 37" C. This amidolytic activity was
converted into nM thrombin via a reference curve obtained with active
site titrated thrombin.
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Fig.2 Influence of SBTI on the thrombin decay constant
I k6." (left ordinate); f ratio t6.. with SBTI/k6"" without
ordinate)
Table 1 The influence of SBTI on thrombin decay
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in plasma
SBTI (right
RatioSBTI
Plasma
Plasma * 0.04 U/ml hep.
Plasma * 1.25 pglml DS
Serum
S e r u m f 0 l U / m l h e p .
2.77 (1s.0)
4.61 (e.1)
4.1,6 (10)
r.63 (2s s)
3.76 (11.r)
2 08 (20.1)
3.47 (r1.9)
3.12 (13 3)
1.1e (3s.3)
2 83 (r4 7)
1,.33
1,.33
r .33
t .37
I . J L
The total decay constant (h + k) is given in
life times in s DS : dermatan sulfate
min-1, in brackets the half
of factors II, VII, VIII, IX, X, XI and XII did not significantly change by
the reptilase treatment (1).
Serum is the material left after plasma has been activated as in a
thrombin generation test (see below).
Euglobulin Fraction
The euglobulin fiaction is obtained from defibrinated pooled plasma
by acid precipitation (pH 5.2) at low ionic strength as described in Josso
and Prou-Wartelle (11). The precipitate is collected by centrifugation and
dissolved in half the initial plasma volume of 21.6 mM trisodium citrate in
buffer A. In order to obtain thrombin, thrombin generation is triggered by
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The AT III concentration is calculated as the difference between the
initial thrombin concentration added and the residual thrombin activity
found. For the measurement in serum, the value obtained is corrected for
o2M-thrombin by subtracting the amidolytic activity of setum, measured
without addition of thrombin. The immunological level of AT III was
determined by radial immunodiffusion on commercial diffusion plates
from Behringwerke AG, Germany. The antibody appeared to recognise
free AI III and not the AI Ill-thrombin complex (see Discussion).
Results
I. Measurements of AT III Breakdown Constant of Thrombin
during the Course of Thrombin Generation
Fig. 1 shows that k1 decreases during the course of thrombin
generation. The presence of heparin (0.03 U/ml) added together
0 0.02 0.04 0.06 0.08 0.1
Heparin Conc. (U/ml)
Fig.3 Influence of unfractionated heparin on the thrombin decay
constant in plasma and in serum. I k6". in plasma; ! k6.. in serum
Table 2 Comparison of AT III determinations in plaSma and in serum
Plasma Serum
Artigenic AT III (%)
Functional AT III (pM)
h=kl IAT II I I(min-l)
frr l [AT II I ]  :  kr '  (min 1/FM)
The antigenic AI III values are obtained in 33 individual plasmas from
normal volunteers and expressed as % of the "normal plasma" that
accompanied the piates. The functional AT III and k1' values were
obtained in normal pool plasma (mean of 12 experiments) and corrected
for the 2:3 dilution in the experimental svstem.
Table 3 Comparison of old and new calculations
with the SBTI increases the decay constants found but the
decrease in the course of the experiment remains. Only a small
change is observed after the peak of the curve, in contrast to the
first minutes of the test, when the constant decreases rapidly. This
explains why we considered the decay constant not to vary on
basis of previous experiments carried out after the peak only (1).
The experiments carried out on endogenous thrombin require a
sufficient amount of thrombin to be generated. They cannot be
performed in plasma or during the first minute of a thrombin
generation test, nor in serum or during the last minutes. In order
to obtain data on plasma and serum one has to add exogenous
thrombin. Because we wanted to remain as close as possible to
endogenously generated thrombin we prepared thrombin by
recalcification of the euglobulin fraction of plasma, a crude
fraction containing all the clotting factors but none of the
inhibitors (11).
II. Comparison of the AT III Constant of Exogenous or
( Endogenous) N ative Thrombin
Before using the euglobulin thrombin preparation it was
necessary to compare the decay constant of this exogenous
thrombin to that of native thrombin generated during the test. To
this end we compared the decay constant of euglobulin-thrombin
to that of the thrombin generated in defibrinated plasma and
added to non-triggered defibrinated plasma. No significant differ-
ence was found between the two values: the half life time of
euglobulin-thrombin under these conditions is 15.4 + 0.4 s, that
of thrombin added from triggered plasma is 15.1 + 0:4 s. The
corresponding overall decay constants (k6.. : kt t k2) are resp.
2.699 ! 0.065 min-1 and 2.784 + 0.073 min-1 (n : 8). These
values are not corrected for the 2:3 dilution of plasma in our
experimental system.
III. Soybean Tiypsin Inhibitor and Thrombin Breakdown
Using exogenous thrombin we have measured k1 in serum. It
turned out to be significantly higher than was to be expected from
previous values obtained near the end of the thrombin generation
curve (1, 2). It appears (Table 1), that the presence of SBTI
(16 pM) decreases ka." by a factor 1.33, both in plasma and in
serum, in the presence and in the absence of heparin and of
dermatan sulfate.
As can be seen in Fig. 2 the effect of SBTI on the thrombin
breakdown constant increases with the SBTI concentration. The
ratio of k6." in the presence and in the absence of SBTI varieS
linearly with the SBTI concentration. This is compatible with a
reversible binding between SBTI and thrombin with an apparent
Ka of -70 pM. The difference between k6"" of endogenous and of
exogenous thrombin therefore appears to be explained by the
addition of SBTI necessary for the inhibition of prothrombin
conversion if the decay of endogenous thrombin is to be meas-
ured.
M The Thrombin Breakdown Constant in Plasma and in Serum
in the Absence and in the Presence of Heparin
The AT Ill-dependent decay constant of thrombin in normal
undiluted plasma is 1.5 times higher than that in the correspond-
ing serum (Table2). Both in plasma and in serum we observed
(Fig.3) that low concentrations of heparin do not influence the
decay constant. The threshold is at 0.01 U/ml in plasma and at
0.04 U/ml in serum (see also discussion). Above the threshold
value ft6.. depends linearly on the heparin concentration. The
slope of these lines describes the dependency of ky on the heparin
concentration. In plasma this is 79.5 min-t per I. U. of heparin/ml
Method
1.r2+ 13 69 + 8
2 .24+ 0 .LL  7  49  +  0 .07
3 379 + 0.246 2.274 + 0.090
1.508 1,.522
r .62
1 5 0
1.49
0.99
lHepl(U/ml) [IIa](nM)
Inhibition
%
Prothrombinase
(nM/min)
Inhibition
%
0.00
0.02
0.03
0.04
0.05
B
0.00
002
0 0 3
0.04
0.05
r47.90
119.50
90.30
79.00
58 10
143.00
115.30
87.40
76.40
s6.07
0.00
19.20
38 90
46.60
60.70
0.00
19.40
38.90
46.60
60.80
341.58
309.57
319.18
333.77
350.4',7
234.20
209.01
2L5.54
235 09
217.32
0.00
9.40
6.60
2.30
250
0 0 0
r0.70
8.00
-o.40
7.20
Prothrombinase activities calculated A) counting with AT III consump-
tion, and B) using pseudo first order AI III dependent decay constants.
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Table 4 Specific activities of various heparins
The specific activity values are the rate of increase of ftdec expressed in
min-]/pM AT III/(pg Hep./ml).
thrombin concentration and the decay constants of thrombin (1).
The reasoning behind this calculation is that the net changes of
the thrombin concentration are the sum of prothrombin conver-
sion velocity and the thrombin inactivation velocity at any
moment. In these calculations we took k1 as a constant, on the
basis of the fact that we could not find a significant change
between 4 andT min aftei the start of the reaction. From Fig.4 it
is clear that indeed in this time interval the changes in AI III
concentration, and hence of k1, are small. Nevertheless, over the
whole of a thrombin generation experiment k1 cannot realistically
be represented by a constant. We therefore modified the calcula-
tion of the velocity of thrombin decay from va"": (kt + k) lTlto
va"": (k1' [AT III] + k2 + fu) ,* T. As in the previous calculation
[T] is the concentration of free thrombin at the moment of
calculation, obtained from the measured amidolytic activity minus
the contribution of the o2M-thrombin complex. New is [AT III],
i. e. the concentration of free AT III at the moment of calcula-
tion, obtained by subtracting from the initial AT III concentra-
tion the amount of AT III bound in the AT Ill-thrombin complex
(see also Appendix). Thble 3 shows a comparison of the old and
the new way of calculating prothrombinase activities. Although
the absolute values differ, the inhibitions brought about by
heparin are comparable.
Fig.5 depicts the course of the various reactants as calculated
with the new algorithm. The course of the AT III concentration
during coagulation was also calculated from the observed changes
in k1.
VI. The Second Order Decay Constant of Various Heparins
On the basis of the observation that ka."is proportional to both
the concentration of AT III and the heparin concentration, it is a
logical next step to express the antithrombin specific activity of
heparin in terms of the increase of the thrombin decay constant
that it causes at a normalised AI III level.
In Thble 4 we show the specific antithrombin activities of
several current heparins expressed as the increase of k1' caused by
1 pg of heparin per ml plasma normalised to an AT III level of
1 t r M .
Discussion
At any moment during coagulation, the thrombin decay
process can be described as the sum of three inactivation
reactions, due to a) AI III, b) ct2M, and c) o,1-antitrypsin and
miscellaneous minor inhibitors. The rate of decay for each of
these reactions is given by the producf of the thrombin concentra-
tion, the inhibitor concentration and the second-order rate
constant for the reaction. The concentrations of o,2M and a1-
antitrypsin are so high compared to the amounts of thrombin that
they bind [a2M: 3.5 pM inhibiting <0.40 pM thrombin; o1-
antitrypsin: 25 pM inhibiting <0.15 pM thrombin (1)], that they
may be considered as constant over the course of a thrombin
generation experiment. These reactions thus follow pseudo first-
order kinetics with a first-order rate constant equal to the product
of the inhibitor concentration and the second-order rate constant.
This is not the case for AI III, however. In normal plasma
about two thirds of the total amount of prothrombin converted,
i. e. -L pM will end up as thrombin captured by AI III, which
accounts for a decrease of AT III from 2.5 1tM to 1.5 pM
(Table 2). It is remarkable that the immunodiffusion apparently
assesses free AT III only. Probably by the interaction with
thrombin and/or by the interaction of the AT Ill-thrombin
complex with vitronectin (13) the antigenic determinants of
AT III are masked.
Total
Standard heparin
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Fig.4 Nl III consumption during the thrombin generation test,
a AI III level calculated from tri drawn line: calculated level of AT III
0 2 4 6 8 1 0 1 2 1 4 1 6
Time (min)
Fig.5 A thrombin generation curve and the calculated course of
different reactants, I Experimental data (1eft scale); A free thrombin
(calculated, left scale); * minor inhibitors-thrombin complex (calculated,
right scale); n a2M-thrombin complex (calculated, right scale); * AT III-
thrombin complbx (calculated, right scale)
or 15.44 min l per pg heparin/ml. In serum it is 55.9 min-1 per
unit heparin/ml or 10.85 min-' per pg heparin/ml. Thus in serum
it is about 1.5 times lower than that in plasma. This is the same
ratio as between the plasma antigenic AT III level and the serum
antigenic AT Illlevel, which, if we admit that only free AT III is
revealed by the antibody (see Discussion), suggests that k1 is
proportional to both the AT III concentration and the heparin
concentration. Indeed, a second order rate constant (k1') i.e. k1
expressed per pM AT III, appears to be identical in plasma and
serum (Table 2).
V A Better Approximation of Prothrombinase Activity
In a previous article we have shown that it is possible to obtain
the course of the velocity of prothrombin conversion (i. e. the
course of the prothrombinase activity) from the course of the
t39
Because of AT III consumption during coagulation, second-
order kinetics must be used for the description of the AT III
dependent  th rombin  decay .  i .  e . :
',' : kt'[AT III] [IIa]
instead of
r' : ftr [IIa].
The situation is different when measuring thrombin decay
constants. In this type of experiment typically only 100 nM of
thrombin will be complexed to AT III so that for all practical
purposes the AT III concentration may be considered constant
over  the  course  o f  such an  exper iment .
Heparin will increase the contribution of the AT III dependent
decay but does not influence the other inhibitors (2). Only at
heparin concentrations that are not usually reached in therapeutic
or preventive situations, and that are not discussed here, will
heparin cofactor II start to play a role (3).
AT III binds thrombin first in a reversible complex which can
then be transformed to an irreversible covalent complex The K6
of the former complex is rather high. Heparin acts by reversibly
associating with AT III. The affinity of the heparin-AT III
complex for thrombin is higher than that of AT III alone by
several orders of magnitude. The rate constant for the formation
of the irreversible thrombin AT III complex is not altered (14).
Thus, the rate of inactivation of thrombin is proportional to the
amount of antithrombin-heparin complex under the non saturat-
ing conditions prevailing in plasma.
In plasma we find a linear dependence of the rate of thrombin
decay on both the heparin and the AT III concentration (Fig.3,
'fable2). This means that the amount of bound heparin is
dependent upon the AT III concentration. It is not automatically
evident from theory why this proportionality exists. In a purified
system it is absent, which is logical because the concentration of
high affinity heparin is in the order of 1 nM and AT III is usually
in large excess (-500 nM), so that all heparin is bound to AT III
and the decay velocity of thrombin will be practically independent
upon the AT III concentration and linearly dependent upon the
heparin concentration (9, 10).
The proportionality in plasma can be explained if we admit that
heparin is partitioned between AT III and other plasma proteins
with which it forms complexes that are inactive on thrombin. In
that case the amount of AT III present will determine how
successfully AT III can compete with other heparin-binding
plasma proteins.
Heparin is known to bind to many plasma proteins such as
albumin, fibrinogen, fibronectin, lipoproteins. To histidin-rich
glycoprotein (HRGP, plasma concentration -5 pM) it binds with
high affinity (Ka : 7 nM) (15-17). We surmise that apart from
HRGP there may be several more heparin binding proteins
responsible for the observed proportionality of heparin depen-
dent thrombin inhibition with the heparin concentration.
The concentration of the AT III heparin complex (C) in the
presence of AT III (A) and one other protein (B) binding heparin
with a dissociation constant of Kp1, is given by:
C : Hror)t Atotl ()\ Affi + Ko")
where
) . :1 -  Bb] (@. t  +  Kor )  ( l I )
in the case of Kpu * L Aror, as is true for HRGP (Kp. -160 nM,
)' A6t -2 nM) equation I reduces to:
C : Htor), Alol Keu (III)
which states that C, and therefore the AI III dependent thrombin
decay velocity, is indeed linearly proportional to the AT III
t40
concentration under the above conditions. Therefore, the interac-
tion of heparin and HRGP alone could explain that the amount of
heparin bound to AT III is dependent upon the heparin concen-
tration as well as upon the AT III concentration. This property is
not affected by the presence of more proteins binding heparin
reversibly with different affinity. Note also that it follows from the
above equations that the thrombin decay velocity in the presence
of heparin is relatively insensitive to variability in the concentra-
tions of other heparin binding proteins, because already for
HRGP a lone 8 , . , ,  )  Kp .
The threshold phenomenon seen in Fig.3 is most likely
explained assuming that a certain low amount of heparin binds
(perhaps irreversibly) to some plasma component with a much
higher affinity than to AT III. The K6 must be in the sub-
nanomolar range, but the concentration, equivalent to 0.01 U/ml
heparin, should be low: -0.35 nM. It remains unexplained why
during the clotting process this high affinity plasma component
increases. Tiaces of platelet factor 4 (pf4) might explain the
phenomenon in plasma but not the increase observed in serum
obtained from platelet poor plasma.
The effect of SBTI on the decay constant of thrombin is most
easily explained by a reversible interaction between SBTI and
thrombin. This interaction does not involve the active site since
SBTI has no influence on the amidolytic activity of thrombin
(data not shown). From the fact that the same effect is seen with
an AT III and an HC II dependent reaction, and because SBTI is
a known inhibitor of serine proteases we presume that it binds to
thrombin without impairing its catalytic activity but hindering its
interaction with antithrombins. Because the SBTI effect is
identical in the presence and in the absence of heparin, it does not
affect the conclusions of our previous work.
The proportionality of k1 with the concentration of AT III has
its consequences for the calculation of prothrombinase activity.
We previously measured k4ss zt 2 min after the thrombin peak,
when prothrombin conversion had largely stopped but a sufficient
amount of thrombin was still present. However, the AT III
concentration by that time is already close to its serum concentra-
tion and Aa". is near its minimum value. k6". is subsequently used
to calculate the thrombin decay velocity for the entire thrombin
generation curve. This leads to an underestimation of the
thrombin breakdown velocity for all but the final part of the
thrombin generation curve. Since the prothrombin converting
activity is calculated as the sum of the observed rate of change of
the thrombin concentration and the calculated thrombin decay
velocity, it is underestimated as well. Measuring thrombin decay
by addition of exogenous thrombin in non activated plasma which
still contains 100% AT III, and counting with the consumption of
the AT III concentration during coagulation when caliulating
thrombin decay rates solves this inaccuracy (cf. Annexe). As
expected (Table 3) prothrombinase activities calculated in this
way are higher. On the other hand, the relative differences
between prothrombinase activities calculated for different experi-
ments remain roughly the same. Thus, the main conclusions from
our previous work involving the lack of inhibition of prothrom-
bine conversion in the presence of heparin are not affected. It
should be noted that the effect of inhibitor consumption on
thrombin decay is even more pronounced in the case of heparin
cofactor Il/dermatan sulfate, since the concentration of HC II is
about 50% of the plasma AT III concentration. Thus HC IIl
dermatan sulfate dependent thrombin decay may diminish quite
dramatically over the course of a thrombin generation experi-
ment. It implicates that the only valid way to measure the effect of
dermatan sulfate on thrombin breakdowns is to measure the
decay of exogenously added thrombin in non activated plasma.
The modifications to the algorithm for calculating prothrom-
binase activities from thrombin seneration curves are
(r)
implemented in the computer programme "Thrombinoscope" (1)
which can be obtained from the authors.
The main conclusion from the results presented is that both in
the absence and in the presence of heparin the rate of AT III
dependent thrombin decay during the course of coagulation in
plasma is proportional to the amount of AT III present. This
allows to define a standard independent unit of heparin (18): One
standard independent unit (5. I. U.) of heparin antithrombin
activity is that concentration of heparin that increases the decay
constant of thrombin in plasma by one inverse minute per pM of
available AT III. Or, in other words, one S.I. U. is the concentra-
tion of heparin that increases by 1 min*' the AI III dependent
second-order decay constant of thrombin in plasma that contains
1 pM of AT IIL Plasmas as a rule will not contain 1 pM of AT III
but the results obtained with an arbitrary normal plasma can be
expressed in that way by deviding the values found by the AT III
content of the plasma. With this unit one can unequivocally
express the specific antithrombin activity of a heparin in S.I. U.
per unit weight of heparin (Table a). We are currently performing
experiments that show that anti-factor Xa activity can be treated
analogously.
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ANNEXE
An Improved Algorithm for the Calculation of Prothrombinase
Activity
H. Kessels, G. M. Willerns, H. C. Hemker
Pr othromb inas e Activ ity
The rate of change (V) of the thrombin concentration (7) in
plasma is defined by the rate of thrombin formation (prothrom-
binase activity, P) and the rate of thrombin breakdown (D);
v(t) : dTtdt: P(t) - D(t). (I)
V(t) can be obtained from the measured course of the amidolytic
activity. D(t) is determined from the independently measured
thrombin decay constants and the thrombin concentration Z(/).
The prothrombinase activity P(t) is then calculated by summing
D(t) and V(t) for each time point.
Thrombin Concentration
The experimentally determined amidolytic activity Ei at time
point Ir reflects the thrombin concentration ?l at this point and the
concentration of the alpha2-macroglobulin-thrombin complex
MT; at time ti:
E i :  T i  + /MT, (r)
Since the o2M-thrombin complex has not the same activity
towards the chromogenic substrate 52238 as free thrombin, a
factor f is necessary. The value of / has been determined to be
0.556.
Thrombin Decay
Thrombin in a plasma is inhibited by a number of serine
protease inhibitor proteins I giving rise to an essentially irrevers-
ible complex C:
T * I - - - > C .
The rate of formation of C is then given by
dCldt : -dlldt: k I(t) T(t).
Serine protease inhibitors relevant to thrombin breakdown in
plasma are Antithrombin III (A), a2-Macroglobulin (M), Hepann
Cofactor II (H), and a number of serpins with a relatively
unimportant anti-thrombin activity (R). -the concentration of o2M
(M) does not decrease significantly during coagulation, nor does
the concentration of the group of inhibitors of secondary import-
ance (R). Therefore, it is reasonable to assume first order kinetics
t4l
for the inactivation of thrombin tiy these inhibitors:
D(t) :[kr'A(t) + k4'H(t) + k2+ h]T(t)
with k2: kz' M and k, : P.' P.
(rr)
Procedure
In practice the course of amidolytic activity is measured at
discrete time points about 30 s apart. The rate of change of the
thrombin concentration at time i - 1 is estimated as the average
rate of change between time i - 1 and time i:
V i - t :  ( T i  -  T i - ) l ( t t  -  t i  t ) .
Values of the first-order decay constants for thrombin due to o2M
and due to minor inhibitors, and of the second-order decay
constants for thrombin due to AI III and HC II are measured in
separate experiments. Prothrombinase calculations are then car-
ried out by a computer program according to the following pseudo
code:
an array E contains the measured amidolytic activities
an array / contains the timepoints of measurement of these
amidolytic activities
As: user input
I1o: user input
M T o : 6
R T 6 : g
Z o : 0
kt', kz, k3, ka': user input
for I : 1 to number-of-points do
begin
L , t :  t i  -  t i - r
MTr : MT;-r * k2 * Ti 1x L't
RT; :  P1--r I  k3 + T; 1* A't
A i :  A i - t  -  k t '  *  A i - r  *  T ;  1 x  A , t
H i :  H i  t  -  k + '  *  H i - r +  T i  t x  L 1
T i :  E i  - / x M T ;
v i_ t  :  LT IL t  :  (T i  -  T i_ ) l  L t
Di-t  :  (k1' x Ai 1 + k2 + k3 + k4' x Hi 1) x Ti-1
P i - t :  V ; - 1  - t  D i  1
Oi :  T i+  MTr  +  RTr  +  Ao -  A t  +  Ho -  H i
end.
The arrays and variables used represent the following quantities
T: thrombin concentration
.8.' experimentally determined amidolytic activity
A: Nl III concentration
H: HC II concentration
MT: o2M-thrombin-complex concentration
RT: other-inhibitors-thrombin-complex concentration
V: delta of thrombin concentration
D: velocity of thrombin decay
P: velocity of thrombin formation (prothrombinase activity)
O: quantity of prothrombin converted
t. ' t ime
kl, ka': second-order decay constants for AT III and HC II
k2, k3: first-order decay constants for a2M and Rest
Estimation of the u2 Macroglobulin Dependent Decay Constant
Since the complex of o2M and thrombin has residual amidolytic
activity, the o2M dependent decay constant ks can be estimated
directly from thrombin generation curves. First, thrombin con-
centrations are calculated from amidolytic activities using a range
of values rc for f k2. These calculated thrombin concentration 7*
are related to the real (but unknown) thrombin concentrations T
in the following manner:
T*(t) : T(t) + (f k2 - o)oJ'"-" G -') T(r)dr. (D
If it is assumed that prothrombin conversion has stopped at a
timepoint fu then
T(t) : T(ti e (kr + k2) (t - to) , t 7ts. (ID
If it is further assumed that T ( t) : g ulLt rn and that k1 * k2* t<, then
it follows from (I) and (II) that:
T*(t) : (f kz - r) 6' 
"-x 
(r- ro) (rr)
where C is the following constant:
C :o['o e "on ") z(r,)dr.
-Ihls, T.(t)le K (t t0) is a constant value for a given rc after
timepoint to. Toft) I e-" 0 - to) ir then plotted as a function of rc, and
k2 is determined from the intersection of this function with the
horizontal axis.
I42
